NCT05461027Completed
Percutaneous Cryoablation of Central Kidney Tumours With Temporary Renal Artery Occlusion
Source: ClinicalTrials.gov · Last updated 27 Dec 2024
Brief summary (registry, in English)
Percutaneous cryoablation is an alternative to urological surgery for T1a tumours, whose oncological efficacy decreases for the most central tumours due to a cold sink effect.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 16 (actual)
- First submitted
- 12 Jul 2022
- Start date
- May 2022
- Primary completion date
- Dec 2023
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Kidney cancer
- NCT number
- NCT05461027
What you commit to
- Study type: Observational
- Participants enrolled: 16
- From May 2022 to the primary completion date, Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Subject having expressed his/her opposition to participate in the study
- Subject under legal protection, guardianship or curatorship
Who the study is looking for
- Adult subject (≥18 years)
- Subject who has undergone cryoablation of a central kidney tumour with temporary occlusion of the renal artery by an endovascular balloon at the HUS during the period 01/01/2018 to 30/12/2021
- Subject who has not expressed his/her opposition, after information, to the re-use of his/her data for the purpose of this research.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service d'Imagerie Interventionnelle - CHU de Strasbourg - France Coordinator of this site? Confirm its status | Strasbourg | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.